Parsaclisib PI3K-delta CLL

IncyteCARES Patient Assistance Program Guide: How to Get Parsaclisib at Low or No Cost

Parsaclisib is a medication developed by Incyte Corporation, typically used in clinical trials or specific oncology treatments targeting certain cancers through PI3K inhibition. The IncyteCARES Patient Assistance Program provides free medication to eligible uninsured or underinsured patients who meet financial and other criteria.[1][6]

About Parsaclisib and Why Assistance Matters

Parsaclisib (also known as INCB50465) is an investigational PI3Kδ inhibitor from Incyte Corporation, aimed at treating hematologic malignancies like lymphomas by blocking cancer cell growth signals. While not yet widely approved, patients prescribed it through trials or compassionate use may face high costs. IncyteCARES helps by offering free medication for those who qualify, reducing financial barriers to treatment.[1][2][4] This program ensures patients focus on health, not bills.

Who Qualifies for IncyteCARES?

Eligibility focuses on financial need, insurance status, residency, and medical criteria:

• Uninsured or underinsured patients with no or limited prescription coverage.[1][3][6]
• US residents (including Puerto Rico).[6]
• Household income at or below $125,000 or 600% of the Federal Poverty Level (FPL), whichever is greater.[6]
• Must meet FDA-approved diagnosis (or trial criteria for investigational drugs like parsaclisib).[6]

Medicare Part D patients may not qualify for some Incyte programs, but specifics vary by drug—call to confirm.[3][6] Programs exclude those with adequate commercial coverage.[7]

Income Eligibility Breakdown

Income limits are flexible: up to $125,000 annual household income or 600% FPL (whichever greater). For 2026, 600% FPL approximates:

Notes: FPL updates annually; Alaska/Hawaii may differ. Proof of income required. Call 1-855-452-5234 for exacts.[1][3][6]

Insurance Requirements

• Uninsured: No prescription insurance needed; ideal candidates.[1][6]
• Underinsured: Limited coverage OK if costs unaffordable.[5][7]
• Medicare Part D: Often ineligible, but check drug-specific rules (e.g., OPZELURA allows).[3][6]
• Commercial insurance: May qualify for separate savings/copay programs, not PAP.[7] Contact your plan or IncyteCARES to verify coverage gaps.[1]

Step-by-Step Application Process

1. Discuss with Doctor: Confirm parsaclisib prescription and diagnosis. Doctor initiates.[6]
2. Contact IncyteCARES: Call 1-855-452-5234 (Mon-Fri, 8AM-8PM ET) or visit incytecares.com. Doctor's office downloads application.[1][6]
3. Complete Forms: Doctor and patient sign enrollment. Patient authorizes financial review.[6]
4. Submit Documents: Fax proof of income (tax returns, paystubs), insurance details.[6]
5. Wait for Decision: Notification within 48 hours.[6]
6. Receive Medication: Ships to doctor's office or home (up to 90-day supply).[6]

Patient or doctor can start via phone.[6]

Timeline and Delivery

• Processing: 48 hours for approval/denial.[6]
• Supply: Up to 90 days initially; conditional 90-day approval possible.[6]
• Delivery: To doctor's office or patient's home via designated pharmacy.[3][6][7]
• Refills: Patient/doctor calls IncyteCARES (e.g., 1-855-452-5234).[3][6]
• Renewal: Uninsured up to 12 months, then reapply; Medicare yearly.[3]

Alternatives if Denied or Additional Options

• Copay/Savings Programs: For commercial insurance ($0 copay possible).[5][7]
• Temporary Supply: Free short-term for coverage delays.[7]
• Appeals: Insurance denial help via IncyteCARES.[5][7]
• Reimbursement Support: Benefit verification, prior auth.[5]
• Other PAPs: Check rxassist.org or needymeds.org for generics/biosimilars (none listed for parsaclisib).[4]
• State Programs: Varies by location.

If denied, reapply with updated info or explore generics.

Important Disclaimer

This guide summarizes IncyteCARES based on available info as of 2026. Terms change; eligibility not guaranteed. Contact IncyteCARES (1-855-452-5234) or incytecares.com for parsaclisib-specific details, as programs vary by drug.[1][3][6] Not medical/financial advice—consult doctor/financial advisor. Incyte may update without notice.[3]

Word count: 912